Sponsors (8)
The bill aims to lower drug prices and expand competition and transparency—benefiting patients, public programs, and purchasers—but does so by using compulsory licensing, foreign price benchmarks, and heavy reporting/enforcement that could reduce industry incentives for innovation, create regulatory complexity, and raise litigation and compliance costs.
Patients (including those with chronic conditions), Medicare and Medicaid beneficiaries, and other payers will likely pay lower drug prices and face lower out-of-pocket and program spending because the bill identifies 'excessive' prices, enables open licensing and earlier generic/biosimilar entry, and caps certain procurement prices.
Patients (and purchasers) could gain faster access to lower-cost generics and biosimilars because the bill allows waiving exclusivities, issues open non-exclusive licenses, and enables competitors to enter sooner.
The bill increases transparency and public oversight by requiring publication of petitions, pricing determinations, manufacturer cost and trial data, and related reports—improving accountability for pricing and allowing consumers, researchers, and Congress to monitor outcomes.
Drug manufacturers, and therefore future R&D investment, could face reduced returns because price recoveries, waived exclusivities, broader licensing, and lowered benchmarks may cut revenues—potentially slowing development of new therapies over time.
If manufacturers respond to lower allowed prices or aggressive enforcement by restricting supply or delaying U.S. launches, patients (especially those with chronic conditions) could face reduced or later access to new therapies.
The bill creates substantial administrative complexity, litigation risk, and regulatory uncertainty—arising from reliance on foreign price data, broad Secretary discretion, new public naming and appeals, and fuzzy statutory terms—which could delay decisions and increase costs for regulators and industry.
Based on analysis of 8 sections of legislative text.
Allows HHS to label brand-name drug prices excessive, void exclusivities, issue open licenses to others, require detailed manufacturer reporting, and impose royalties and penalties.
Authorizes HHS to review brand-name drug prices annually and declare prices "excessive" when U.S. prices exceed a median of five reference countries or on other specified factors. For drugs found excessive, the bill voids government-granted exclusivities, requires issuance of open non-exclusive licenses so others can make or import the drug, and sets rules for reasonable royalty payments and expedited review of generic/biosimilar applications. It also requires detailed annual manufacturer reporting, creates a public database and congressional reports, imposes penalties for false or late reports, and bars coordinated anticompetitive conduct aimed at defeating these measures.
Introduced May 20, 2025 by Bernard Sanders · Last progress May 20, 2025